Malignant Tumor of Lacrimal Drainage Structure Clinical Trial
Official title:
Long-term Outcomes of Neoadjuvant Radiotherapy Versus Adjuvant Radiotherapy for Malignant Lacrimal Sac Tumors (A Multicenter Randomized Controlled Trial)
The treatment for malignant lacrimal sac tumors is difficult and the prognosis is poor. The conventional strategy is surgical resection followed by adjuvant radiotherapy with or without concurrent chemotherapy. This approach has many drawbacks including positive surgical margins due to large tumor size, distant metastasis due to intraoperative squeeze, and implant exposure due to high doses of radiation. In previous research, the investigators innovatively adopted neoadjuvant radiotherapy (or chemoradiotherapy) and withdrew radiotherapy after surgery. Preoperative radiotherapy can effectively reduce the tumor size and encapsulate the tumor in a fibrotic cyst, and therefore enables en-bloc excision of the tumor and simultaneous orbital reconstruction. This multidisciplinary approach can reduce the risk of recurrence and metastasis, lower the dose of radiation, and avoid implant exposure after reconstruction. In order to compare the long-term outcomes between neoadjuvant radiotherapy and conventional treatment approach, the investigators will prospectively recruit 94 patients with malignant lacrimal sac tumors and randomly assign these subjects into the study group (neoadjuvant radiotherapy, 47 cases) and the control group (conventional treatment, 47 cases). The primary outcomes include overall survival, disease-free survival, distant metastasis-free survival, and locoregional control at 2-year, 5-year and 10-year intervals. The secondary outcomes include ocular functions (visual acuity and diplopia, tear film stability and tear secretion, globe dystopia and motility, and corneal topography), acute and chronic radiation-related toxicity, cosmesis (medial canthal tendon dystopia and eyelid retraction), and assessment of quality of life.
| Status | Recruiting |
| Enrollment | 94 |
| Est. completion date | December 31, 2035 |
| Est. primary completion date | December 31, 2023 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 80 Years |
| Eligibility | Inclusion Criteria: - Patients with suggestive symptoms, signs, imaging features and/or biopsy results for malignant lacrimal sac tumors - Regardless of previous operations including silicone tube intubation, endoscopic dacryocystorhinostomy and incisional/needle biopsy Exclusion Criteria: - Recurrent tumors - Metastatic tumors to the lacrimal sac region - Malignant lacrimal sac tumors with previous surgical excision - Malignant lacrimal sac tumors with local nodal or distant metastasis - Special tumor types (e.g. lymphoma) which require non-surgical treatment - Large tumors (invades = 2/3 depth of the orbit) which require orbital exenteration |
| Country | Name | City | State |
|---|---|---|---|
| China | Fudan Eye & ENT Hospital | Shanghai |
| Lead Sponsor | Collaborator |
|---|---|
| Eye & ENT Hospital of Fudan University | Peking University Eye Center, Peking University Third Hospital, Tianjin Medical University Eye Hospital, Zhongshan Ophthalmic Center, Sun Yat-sen University |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | overall survival at 2-year interval | living subjects | 2 years | |
| Primary | overall survival at 5-year interval | living subjects | 5 years | |
| Primary | overall survival at 10-year interval | living subjects | 10 years | |
| Primary | disease-free survival at 2-year interval | tumor-free subjects | 2 years | |
| Primary | disease-free survival at 5-year interval | tumor-free subjects | 5 years | |
| Primary | disease-free survival at 10-year interval | tumor-free subjects | 10 years | |
| Primary | distant metastasis-free survival at 2-year interval | living subjects with no distant metastasis | 2 years | |
| Primary | distant metastasis-free survival at 5-year interval | living subjects with no distant metastasis | 5 years | |
| Primary | distant metastasis-free survival at 10-year interval | living subjects with no distant metastasis | 10 years | |
| Primary | locoregional control at 2-year interval | living subjects without local recurrence or local metastasis | 2 years | |
| Primary | locoregional control at 5-year interval | living subjects without local recurrence or local metastasis | 5 years | |
| Primary | locoregional control at 10-year interval | living subjects without local recurrence or local metastasis | 10 years | |
| Secondary | Visual Acuity | Best-corrected visual acuity (BCVA) will be measured under standardized lighting conditions in the room, and will be converted to logarithm of the minimum angle of resolution (logMAR) values for statistical analysis. | up to 2 years | |
| Secondary | Subjective Diplopia After Surgery | Subjective diplopia will be assessed by categorizing patients according to four grades: no diplopia (absent), diplopia when the patient is tired or awakening (intermittent), diplopia at extremes of gaze (inconstant), and continuous diplopia in the primary or reading position (constant). A change of one grade is considered to be clinically relevant. | up to 2 years | |
| Secondary | Number of Participants with Acute Radiation-Related Toxicity | Acute radiation-related toxicity is defined as events occurring within 1 month after start of radiotherapy, and will be prospectively graded by the treating radiation oncologist according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5). | 1 month | |
| Secondary | Number of Participants with Chronic Radiation-Related Toxicity | Chronic radiation-related toxicity is defined as events occurring or persisting > 3 months after start of radiotherapy, and will be prospectively graded by the treating radiation oncologist according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 5.0 (CTCAE v5). | up to 2 years | |
| Secondary | Health-Related Quality of life | The health-related quality of life will be assessed based on the EORTC (European Organisation for Research and Treatment of Cancer) Quality of Life Questionnaire Core 30 (QLQ-C30) downloaded from https://www.eortc.org. This 30-item questionnaire includes five functional scales, three symptom scales, a global health status / QoL scale, and six single items. The multi-item scales include a different set of items. Each item includes four subscales, namely "Not at all" (1 point), "A little" (2 points), "Quite a bit" (3 points) and "Very much" (4 points).
The score will be recorded during each follow-up, and data will be analyzed for comparison between the study group and the control group. |
up to 10 years | |
| Secondary | Ophthalmic Cancer-Related Quality of life | The ophthalmic cancer-related quality of life will be assessed based on the EORTC (European Organisation for Research and Treatment of Cancer) Quality of Life Questionnaire Ophthalmic Cancer Module 30 (QLQ-OPT30) downloaded from https://www.eortc.org. The QLQ-OPT30 comprises of 30 questions assessing vision impairment (9 items), functional problems due to vision impairment (8 items), eye symptoms (6 items), worry about recurrent disease (2 items), problems with appearance (1 items), problems driving (2 items), headache (1 item), problems reading (1 item). Each item includes four subscales, namely "Not at all" (1 point), "A little" (2 points), "Quite a bit" (3 points) and "Very much" (4 points).
The score will be recorded during each follow-up, and data will be compared between the study group and the control group. |
up to 10 years |